Oakview Capital Management L.P. Decreases Stake in Pfizer Inc. (PFE)

Oakview Capital Management L.P. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 591,284 shares of the biopharmaceutical company’s stock after selling 138,503 shares during the quarter. Pfizer comprises approximately 9.3% of Oakview Capital Management L.P.’s holdings, making the stock its 2nd largest position. Oakview Capital Management L.P.’s holdings in Pfizer were worth $26,058,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Montag A & Associates Inc. raised its stake in Pfizer by 1.7% during the second quarter. Montag A & Associates Inc. now owns 192,933 shares of the biopharmaceutical company’s stock valued at $7,000,000 after purchasing an additional 3,263 shares in the last quarter. Sigma Planning Corp raised its stake in Pfizer by 4.0% during the second quarter. Sigma Planning Corp now owns 142,081 shares of the biopharmaceutical company’s stock valued at $5,155,000 after purchasing an additional 5,446 shares in the last quarter. Advanced Asset Management Advisors Inc raised its stake in Pfizer by 45.3% during the second quarter. Advanced Asset Management Advisors Inc now owns 67,002 shares of the biopharmaceutical company’s stock valued at $2,431,000 after purchasing an additional 20,903 shares in the last quarter. Vicus Capital raised its stake in Pfizer by 21.5% during the second quarter. Vicus Capital now owns 40,894 shares of the biopharmaceutical company’s stock valued at $1,484,000 after purchasing an additional 7,236 shares in the last quarter. Finally, Hugh Johnson Advisors LLC raised its stake in Pfizer by 4.2% during the second quarter. Hugh Johnson Advisors LLC now owns 39,284 shares of the biopharmaceutical company’s stock valued at $1,425,000 after purchasing an additional 1,589 shares in the last quarter. Institutional investors own 70.61% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Thursday, January 31st. Credit Suisse Group raised shares of Pfizer from a “neutral” rating to an “outperform” rating in a research note on Thursday, January 31st. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, UBS Group downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 23rd. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $44.68.

In related news, EVP Douglas M. Lankler sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the transaction, the executive vice president now owns 83,592 shares of the company’s stock, valued at approximately $3,573,558. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Douglas M. Lankler sold 38,800 shares of the firm’s stock in a transaction dated Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the completion of the transaction, the executive vice president now directly owns 83,592 shares in the company, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Shares of PFE opened at $41.87 on Wednesday. Pfizer Inc. has a twelve month low of $34.32 and a twelve month high of $46.47. The firm has a market capitalization of $248.12 billion, a PE ratio of 13.96, a PEG ratio of 2.42 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The company had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The firm’s revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.86 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, February 1st will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.44%. The ex-dividend date is Thursday, January 31st. This is an increase from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

Pfizer declared that its board has approved a stock buyback program on Friday, December 14th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire up to 3.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Oakview Capital Management L.P. Decreases Stake in Pfizer Inc. (PFE)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.com-unik.info/2019/02/13/oakview-capital-management-l-p-decreases-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Put Option

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit